Canada Approves Prescription Melatonin for Sleep Support in Autistic Youth, With Calls for More Research

Canada has approved the first prescription melatonin treatment specifically designed to support sleep in autistic children and adolescents, marking a regulatory milestone as researchers call for more evidence on long-term use. The approval comes as sleep differences affect an estimated 50-66% of autistic youth00211-1/abstract) — compared to 20-30% of non-autistic children — with variations in falling asleep, staying asleep, or sleep-wake cycles being common.

Last month, Health Canada cleared SLENYTO®, an extended-release melatonin tablet, for sleep support in autistic youth or those with Smith-Magenis syndrome. As the Autistic Self Advocacy Network notes, sleep differences in autism often stem from biological factors like melatonin production rhythms, alongside sensory and environmental barriers.

A 2025 Lancet review00211-1/abstract) found it reduces time to fall asleep by an average of 28 minutes and increases total sleep duration by 48 minutes.

Short-term benefits, long-term questions

Multiple peer-reviewed studies confirm melatonin's short-term effectiveness for sleep support. A 2025 Lancet review00211-1/abstract) found it reduces time to fall asleep by an average of 28 minutes and increases total sleep duration by 48 minutes. However, researchers note these findings come primarily from studies lasting weeks to months, not years.

'The growing use of melatonin in young autistic children outpaces our understanding of its long-term impacts,' noted a January 2026 analysis by Science Media Centre España. This gap persists even as over-the-counter melatonin becomes the most common pharmacological sleep support for autistic youth, with U.S. surveys suggesting nearly 1 in 5 school-aged autistic children use it regularly.

Individualized approaches needed

The new Canadian-approved SLENYTO® differs from over-the-counter products in its controlled-release formulation and prescription status, allowing for standardized dosing under medical supervision. Yet most melatonin used by autistic youth globally remains unregulated over-the-counter products, where dosage accuracy and purity vary widely, as Psychiatry Online reported in 2025.

Sleep specialists emphasize that melatonin should complement, not replace, individualized support strategies. As researcher Dr. Emma Sartori told Science Daily in March 2026, 'For many autistic youth, addressing sensory needs, light exposure, and bedtime routines may significantly improve sleep before considering melatonin.'

Autistic adults who used melatonin as children caution about the need for careful monitoring. 'It helped me sleep, but we didn't know then about potential impacts on puberty timing,' shared one contributor to the Autism Sleeps Project, a community-led research initiative.